Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

sels with excellent

specificity. The high degree of selective targeting seen in the study

provides additional evidence of bavituximab's therapeutic potential.

Bavituximab Anti-Viral Program: During the third quarter, the company continued to advance its bavituximab HCV program and presented positive data at a key liver disease meeting.
-- Added The Johns Hopkins Hospital and a private clinic in Orange

County, California as additional clinical study sites for the HCV/HIV

co-infection study.

-- Presented final results from the Phase I multiple dose HCV trial at

the prestigious Annual Meeting of the American Association for the

Study of Liver Disease that showed bavituximab was well tolerated and

demonstrated encouraging signs of anti-viral activity.

Cotara(R) Glioblastoma Program: Peregrine continued to advance the Cotara brain cancer program.
-- Added additional study sites and continued patient dosing and

follow-up in the Cotara Phase II study in patients with glioblastoma

multiforme, the most deadly form of brain cancer. Eight sites are now

open for patient enrollment.

-- Added an additional site, the Barrow Neurological Institute (BNI) in

Phoenix, Arizona, to the ongoing Cotara dosimetry and dose

confirmation clinical study. BNI also participated in a previous

Cotara Phase II clinical trial.

-- Announced positive results from the first cohort of patients treated

in the Cotara dosimetry trial and from the initial patients treated in

the Cotara Phase II trial. Cotara appeared safe and well tolerated

with no dose-limiting adverse events, with continuing patients being

monitored for overall survival. Several patients in these studies

have lived longer than the six-month expected median survival time for

this patient po
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... If you're on the Midwest technology job market today, ... You've also learned something about interviewing, thank-you letters and ... ,If youre an older job seeker, though, you may ... to surmount your search: your age. Wait. Isn't age ...
... the weeks since, I've been asked many times why the ... of course, one very practical reason: No compelling new services ... that's the easy out. , ,As I've written before, social ... a clear avenue to revenue that returns value to customers ...
... Wisconsin-based businesses and organizations have formed a unique ... efforts of the Medical College of Wisconsin Research ... commercialization activities. The foundation announced the funding along ... Marketing and Licensing, whose primary purpose will be ...
Cached Biology Technology:How 40-plus tech job seekers can prevent age discrimination 2How 40-plus tech job seekers can prevent age discrimination 3How 40-plus tech job seekers can prevent age discrimination 4Social Networks Revisited 2Social Networks Revisited 3Medical College gets support to expand technology commercialization 2Medical College gets support to expand technology commercialization 3Medical College gets support to expand technology commercialization 4
(Date:4/18/2014)... researchers led by a University of California, Riverside professor ... million Department of Defense grant to uncover fundamental design ... the predictable design of light-weight, tough and strong advanced ... plants and animals, including the mantis shrimp, toucan and ... constructed over millions of years and coming up with ...
(Date:4/17/2014)... of stem cell therapies to cure a variety of ... populations based on cell surface markers. Researchers from the ... is highly expressed in a type of stem cells ... in an article in BioResearch Open Access , ... The article is available free on the ...
(Date:4/17/2014)... births, Down syndrome - or trisomy 21 - is ... results from a chromosomal abnormality where cells of affected ... of the human genome). A study conducted by Stylianos ... Medicine and Development at the University of Geneva (UNIGE) ... light on how the extra chromosome 21 upsets the ...
Breaking Biology News(10 mins):Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... soldier is wounded during combat, surgeons must focus on ... that could improve the repair and regeneration processes are ... they are not being moved quickly enough into military ... Tech Center for Advanced Bioengineering for Soldier Survivability want ...
... person who dies suddenly should always be referred for ... they too are at risk of sudden death, a ... of Human Genetics today (Tuesday 26 May). ... the Department of Cardiogenetics, Academic Medical Centre, Amsterdam, The ...
... IMMEDIATE RELEASE An advance in solving the mysterious ... Scientists in Ohio are reporting a ... than one million machinists in the United States who ... fluids. Those fluids become airborne during machining of metal ...
Cached Biology News:New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 2New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 3Comprehensive cardiogenetic testing for families of sudden unexplained death victims can save lives 2American Chemical Society's Weekly PressPac -- May 20, 2009 2American Chemical Society's Weekly PressPac -- May 20, 2009 3American Chemical Society's Weekly PressPac -- May 20, 2009 4American Chemical Society's Weekly PressPac -- May 20, 2009 5American Chemical Society's Weekly PressPac -- May 20, 2009 6American Chemical Society's Weekly PressPac -- May 20, 2009 7American Chemical Society's Weekly PressPac -- May 20, 2009 8American Chemical Society's Weekly PressPac -- May 20, 2009 9American Chemical Society's Weekly PressPac -- May 20, 2009 10
Request Info...
...
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research ... availability of new radiolabeled ligands selected to ... a wide range of products and services ... over 400 state-of-the-art radioligands. If you do ...
Request Info...
Biology Products: